SLAMF3 is expressed on MM cells regardless of disease progression or cell phenotype and is detected not only on CD38+CD138+ plasma cells but also on aberrant CD56+ plasma cells and CD38+CD138low/negative chemotherapy-resistant myeloma progenitor cells [62,63]. Here, NCAM1 is linked to Miyoshi myopathy.